Optimizing the live attenuated influenza A vaccine backbone for high-risk patient groups
J. P. Bonifacio, N. Williams, L. Garnier, S. Hugues, M. Schmolke, B. Mazel-Sanchez
This study modifies the LAIV backbone to enhance safety while maintaining immunogenicity, showing reduced replication and no loss of protective efficacy.
bioRxiv · Oct 6, 2021Microbiology